Smart-Money SignalNeutral · 47/100— Insiders are net buyers over 90 days ($2.7M, 14 buys vs 2 sales)
Revenue$11.5B
Net Income$1.8B
EPS$3.72
Market Cap$165.4B
Price Performance
Historical data including institutional events
Company Profile
R
Robert B. Ford
CEO & Executive Director
Paritaprevir is an acylsulfonamide inhibitor of the NS3-4A serine protease manufactured by Abbott Laboratories that shows promising results as a treatment of hepatitis C. When given in combination with ritonavir and ribavirin for 12 weeks, the rate of sustained virologic response at 24 weeks after treatment has been estimated to be 95% for those with hepatitis C virus genotype 1. Resistance to treatment with paritaprevir is uncommon, because it targets the binding site, but has been seen to arise due to mutations at positions 155 and 168 in NS3.
